• 1
    Anonymous. Women and minorities less likely than men to receive specialty care. AIDS Alert. 1998;13: 879.
  • 2
    Turner BJ, Mc Kee L, Fanning T, Markson LE. AIDS specialist versus generalist ambulatory care for advanced HIV infection and impact on hospital use. Med Care. 1994;32: 90216.
  • 3
    Shapiro MF, Morton SC, Mc Caffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281: 230515.
  • 4
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Women initiate highly active antiretroviral therapy later than men. J Acquir Immune Defic Syndr. 2000;24: 47582.
  • 5
    Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35: 389416.
  • 6
    Valdez H, Lederman MM, Woolley I, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med. 1999;159: 177176.
  • 7
    Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353: 86368.
  • 8
    Hogg R, Yip B, Chan K, O'Shaughnessy M, Montaner J. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. In: Program and Abstracts of the XIII International Conference on AIDS, Durban, South Africa, July 9–14, 2000. Abstract no. TuOrB419.
  • 9
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV. Ann Intern Med. 2000;133: 2130.
  • 10
    Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30: 10510.
  • 11
    Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, January 31–February 4, 1999. Abstract no. 98.
  • 12
    Gebo KA, Moore RD. Correlation of social stressors, illicit drug use, and health beliefs with adherence to antiretroviral regimens. RWJ Clinical Scholars Program, Ft. Lauderdale, November 2000.
  • 13
    Montaner J, Hogg R, Yip B, et al. Predictors of compliance with triple combination therapy among HIV-positive men and women in British Columbia. In: Program and Abstracts of the XIII International Conference on AIDS, Durban, South Africa, July 9–14, 2000. Abstract no. TuPpD1200.
  • 14
    Abriola K, Mc Nabb JC, Ross J, et al. Adherence to HAART by MEMS predicts virologic outcome in minority/IVDU clinic population. In: Program and Abstracts of the XIII International Conference on AIDS, Durban, South Africa, July 9–14, 2000. Abstract no. TuOrB416.
  • 15
    Arabe J, Rubini NP, Rodrigues AC, et al. Factors which influence adherence to the use of protease inhibitors. In: Program and Abstracts of the XII International Conference on AIDS, Geneva, Switzerland, June 28–July 3, 1998. Abstract no. 32404.
  • 16
    Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18: 33137.
  • 17
    Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48: 13541.
  • 18
    Knowlton AR, Latkin CA, Schroeder JR, Hoover DR, Ensminger M, Celentano DD. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 2001;13: 54959.
  • 19
    Coelho R, Rangel R, Ramos E, Martins A, Prata J, Barros H. Depression and the severity of substance abuse. Psychopathology. 2000;33: 1039.
  • 20
    Powell-Cope GM, White J, Henkelman EJ, Turner BJ. Qualitative and quantitative assessments of HAART adherence of substance abusing women. AIDS Care. In press.
  • 21
    Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, Smith D. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS. 1999;13: 245968.
  • 22
    Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160: 21017.
  • 23
    Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16: 76774.
  • 24
    Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17: 37781.
  • 25
    Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in post-partum HIV-infected women. Med Care. 2000;38: 91125.
  • 26
    Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285: 235562.
  • 27
    Laine C, Hauck WW, Turner BJ. Outpatient pattern of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Med Care. 2002;40: 97695.
  • 28
    Christiansen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, Lo Gerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997;35: 116470.
  • 29
    Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95: 16773.
  • 30
    Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
  • 31
    Rawson RA, Shoptaw SJ, Obert JL, et al. An intensive outpatient approach for cocaine abuse treatment. J Subst Abuse Treat. 1995;12: 11727.
  • 32
    Anonymous. Designated care programs for patients with AIDS and HIV-related illnesses in designated care centers. N Y State J Med. 1989;89: 5423.
  • 33
    Anonymous. State of New York Department of Health Memorandum. Health Facilities Series: H-23, D&TC-17, HMO-16. New York State Department of Health; 1993: 936.
  • 34
    Williams JW Jr., Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132: 74356.
  • 35
    Sambamoorthi U, Walkup J, Olfson M, Crystal S. Antidepressant treatment and health services utilization among HIV-infected Medicaid patients diagnosed with depression. J Gen Intern Med. 2000;15: 31120.
  • 36
    Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the millennium. JAMA. 2001;285: 118692.
  • 37
    Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285: 146674.
  • 38
    Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997;54: 100915.
  • 39
    Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27: 25159.
  • 40
    Laine CL, Newschaffer C, Zhang D, Rothman J, Hauck WW, Turner BJ. Models of care in New York State Medicaid substance abuse clinics: range of services and linkages to medical care. J Subst Abuse. 2000;12: 27185.
  • 41
    Dwight-Johnson M, Sherbourne CD, Liao D, Wells KB. Treatment preferences among depressed primary care patients. J Gen Intern Med. 2000;15: 52734.
  • 42
    Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry. 1999;60: 74146.
  • 43
    Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156: 1017.
  • 44
    Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv. 2001;52: 161520.
  • 45
    Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci. 1998;20: 737.
  • 46
    Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279: 145862.
  • 47
    Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. [Editorial]. Ann Intern Med. 2001;134: 10046.
  • 48
    Maher K, Klimas N, Fletcher MA, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs Medical Center. J Acquir Immune Defic Syndr. 1999;22: 35863.
  • 49
    Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23: 36061.